<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940442</url>
  </required_header>
  <id_info>
    <org_study_id>61810</org_study_id>
    <nct_id>NCT04940442</nct_id>
  </id_info>
  <brief_title>Outreach and Choice in Colorectal Cancer Screening</brief_title>
  <official_title>Outreach and Choice in Colorectal Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical trial will be to compare overall colorectal cancer&#xD;
      (CRC) screening participation between an active choice (fecal immunochemical test [FIT] or&#xD;
      colonoscopy) and a sequential choice (FIT offered first, then colonoscoscopy offered in those&#xD;
      still unscreened) arm. Secondarily, we will (1) compare the proportions of FIT vs.&#xD;
      colonoscopy per arm, (2) compare active choice vs FIT only in the initial 3 months of the&#xD;
      study, (3) characterize changes in physician knowledge and attitudes regarding CRC screening&#xD;
      before and after an educational seminar delivered at the launch of the initiative, (4)&#xD;
      characterize perceptions regarding the effect of the intervention on clinical practices, and&#xD;
      (5) compare detection rates of CRC, adenomas and SSLs per arm, and the operational results of&#xD;
      the outreach program across arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with screening completion</measure>
    <time_frame>6 months from initial offer</time_frame>
    <description>Number of patients with FIT or colonoscopy completed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Colorectal Cancer Screening</condition>
  <arm_group>
    <arm_group_label>Active choice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FIT or colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential choice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FIT offered first, then colonoscopy offered to those still unscreened</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Outreach</intervention_name>
    <description>Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened</description>
    <arm_group_label>Active choice</arm_group_label>
    <arm_group_label>Sequential choice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 45-75 years of age not up to date with CRC screening, and without precancerous&#xD;
             polyp history (i.e. not in post-polypectomy surveillance; ascertained based on problem&#xD;
             list or colonoscopy results letter).&#xD;
&#xD;
          2. The assessment of screening status will happen monthly, on a rolling basis.&#xD;
&#xD;
          3. Definition of being up to date with CRC screening includes any one of the following:&#xD;
&#xD;
             i) FIT or guaiac-FOBT within 1 year, OR&#xD;
&#xD;
        ii) Colonoscopy within 10 years, OR&#xD;
&#xD;
        iii) Sigmoidoscopy within 5 years, OR&#xD;
&#xD;
        iv) CT colonography within 5 years, OR&#xD;
&#xD;
        v) Cologuard within 3 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age outside the 45-75 range.&#xD;
&#xD;
          2. History of precancerous polyps requiring colonoscopy surveillance.&#xD;
&#xD;
          3. Already being up to date with CRC screening, as defined above.&#xD;
&#xD;
          4. Evidence of total removal of the colon which would eliminate the need for screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uri Ladabaum, MD</last_name>
    <phone>6507252850</phone>
    <email>uri.ladabaum@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Primary Care Clinics</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uri Ladabaum, MD</last_name>
      <phone>650-725-2850</phone>
      <email>uri.ladabaum@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Uri Ladabaum</investigator_full_name>
    <investigator_title>Professor Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

